Rasagiline tartrate

Rasagiline tartrate is used experimentally for the treatment of Parkinson’s disease. It works by inhibiting MAO-B, helping to increase dopamine levels in the brain. This improves motor symptoms like tremors, stiffness, and slow movement. It is a research form, while rasagiline mesylate is the clinically approved version. It is grouped under the following drug class(es): Dopamine agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Rasagiline hemitartrate, Rasagiline (TN) and UNII-B9A329CN07. Its PubChem CID is 71550735.

CAS No 136236-52-7
Molecular Formula C28H32N2O6
Molecular Weight 492.6 g/mol
Synonyms (2R,3R)-2,3-dihydroxybutanedioic acid;(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine

Frequently Asked Questions